Short Interest in PDS Biotechnology Corporation (NASDAQ:PDSB) Declines By 22.9%

PDS Biotechnology Corporation (NASDAQ:PDSB) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 542,000 shares, a decrease of 22.9% from the August 31st total of 702,900 shares. Based on an average daily trading volume, of 1,890,000 shares, the short-interest ratio is presently 0.3 days.

PDSB traded down $0.09 on Thursday, reaching $2.24. The company’s stock had a trading volume of 388,948 shares, compared to its average volume of 968,463. The stock has a market cap of $34.41 million, a price-to-earnings ratio of -0.89 and a beta of 2.93. PDS Biotechnology has a 1 year low of $0.62 and a 1 year high of $5.11. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.70 and a quick ratio of 7.70. The business’s 50 day moving average is $2.54 and its 200 day moving average is $1.83.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. As a group, research analysts forecast that PDS Biotechnology will post -1.14 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in PDSB. Bank of New York Mellon Corp bought a new position in PDS Biotechnology during the 1st quarter worth approximately $26,000. Amussen Hunsaker Associates LLC bought a new position in PDS Biotechnology during the second quarter valued at about $27,000. UBS Group AG raised its holdings in PDS Biotechnology by 604.6% during the first quarter. UBS Group AG now owns 38,400 shares of the company’s stock valued at $28,000 after buying an additional 32,950 shares in the last quarter. Lincoln National Corp bought a new position in PDS Biotechnology during the second quarter valued at about $33,000. Finally, Inspirion Wealth Advisors LLC raised its holdings in PDS Biotechnology by 39.2% during the second quarter. Inspirion Wealth Advisors LLC now owns 32,540 shares of the company’s stock valued at $65,000 after buying an additional 9,165 shares in the last quarter. 11.09% of the stock is currently owned by institutional investors.

Several equities research analysts have recently weighed in on PDSB shares. Alliance Global Partners upped their target price on PDS Biotechnology from $4.00 to $6.50 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Chardan Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of PDS Biotechnology in a research report on Wednesday, July 8th. Finally, Zacks Investment Research raised PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Wednesday, July 15th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. PDS Biotechnology has a consensus rating of “Buy” and a consensus target price of $5.94.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. The company develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers.

Featured Article: What is a Reverse Stock Split?

Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.